Cellectis S.A.

ALCLS

FR0010425595

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 16:55:00 12/05/2026 BST			After hours 20:59:25
3.434 ^EUR	+1.66%		3.524	+2.62%

04:15pm	European Equities Traded in the US as American Depositary Receipts Decline Sharply in Tuesday Trading	MT
08:01am	Atos, Fnac Darty, Chargeurs... stocks to watch today in Paris

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down 3% for Week

Published on 11/21/2025 at 04:09 pm GMT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Cellectis S.A.

04:15pm	European Equities Traded in the US as American Depositary Receipts Decline Sharply in Tuesday Trading	MT
08:01am	Atos, Fnac Darty, Chargeurs... stocks to watch today in Paris
07:08am	Cellectis extends cash runway into Q4 2027
05-11	Cellectis S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-11	European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading	MT
05-11	Weekly Earnings Calendar
05-06	European Equities Traded in the US as American Depositary Receipts Climb Sharply Higher in Wednesday Trading	MT
05-05	It's kicking off, but they're still talking
05-04	European Equities Traded in the US as American Depositary Receipts Start Week Lower	MT
05-01	European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week	MT
04-29	European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading	MT
04-27	Cellectis Presents Epigenetic Editing Platform To Turn Genes Off Without Altering DNA	CI
04-24	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	MT
04-21	Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia	CI
04-20	European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading	MT

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR T cells for the treatment of cancer patients, and a platform for for the development of gene therapies in other therapeutic indications. Thanks to its fully in-house production capabilities, Cellectis S.A. is one of the few genome-editing companies to control the cell and gene therapy value chain from end to end.

Employees

227

Sector

Biotechnology & Medical Research

More about the company